New hope for Tough-to-Treat lung cancer: first patients test experimental drug
NCT ID NCT07107490
Summary
This is the first study in people testing a new drug called ALPS12 for extensive stage small cell lung cancer that has returned after prior treatment. The main goals are to find a safe dose and see how the body handles the drug, while also checking for early signs that it might shrink tumors. The study will enroll about 122 patients who have already tried at least one other cancer therapy.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for EXTENSIVE STAGE SMALL CELL LUNG CANCER are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Ehime University Hospital
RECRUITINGTōon, Ehime, 791-0295, Japan
-
Kindai University Hospital
RECRUITINGSakai, Osaka, 590-0197, Japan
-
National Cancer Center Hospital East
RECRUITINGKashiwa, Chiba, 277-8577, Japan
-
Niigata Cancer Center Hospital
RECRUITINGNiigata, 951-8566, Japan
-
Queen Mary Hospital
RECRUITINGHong Kong, Hong Kong
-
Show Chwan Memorial Hospital
RECRUITINGChanghua, 500, Taiwan
Conditions
Explore the condition pages connected to this study.